Valneva Announces Conference Participation
Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a leader in the vaccine industry, is gearing up to present at prominent investor conferences in the United States and Europe. Senior management, including CEO Thomas Lingelbach and CFO Peter Bühler, are slated to participate at the TD Cowen 45th Annual Health Care Conference. This event is set to occur in Boston, where they will also engage with institutional investors.
Insight into Valneva's Vaccine Pipeline
The discussions will encompass Valneva's innovative vaccine candidates, including their noteworthy Lyme disease vaccine, VLA15. This vaccine represents a significant advancement in combating Lyme disease and reflects the company’s commitment to addressing infectious diseases with unmet medical needs. Alongside this, they will also highlight their Shigella and Zika vaccine programs, which are vital components of the company's expanding portfolio.
Revenue Insights for 2025
Valneva anticipates generating substantial revenues from their marketed vaccines, with projections estimating between €170-180 million for the year ahead. This robust revenue stream not only supports their current operations but also fuels ongoing research and development efforts, particularly in advancing first-in-class vaccine solutions for critical health concerns.
Webcast Details for Investors
For those unable to attend in person, the TD Cowen presentation will be available via live webcast, with a recording accessible later on the Valneva website. This opportunity allows a broader audience to stay informed about the company’s progress and innovations within the vaccine sector.
Upcoming Van Lanschot Kempen Conference
Following the TD Cowen event, Valneva will participate in the Van Lanschot Kempen Life Sciences Conference in Amsterdam. At this event, CEO Thomas Lingelbach and CFO Peter Bühler will hold additional meetings with institutional investors, further showcasing the company’s vision and potential within the biopharmaceutical industry.
Company Overview and Growth Strategy
Valneva SE specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. The company leverages its expertise to create vaccines that cater to significant public health needs. Their current lineup includes three proprietary travel vaccines and a partnership with Pfizer to develop the only Lyme disease vaccine candidate in advanced clinical trials.
Investor and Media Contacts
For further inquiries, investors and media representatives can reach out to:
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
Email: laetitia.bachelot-fontaine@valneva.com
Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
Email: joshua.drumm@valneva.com
Frequently Asked Questions
What is Valneva SE primarily focused on?
Valneva SE is focused on developing and commercializing prophylactic vaccines for infectious diseases addressing unmet medical needs.
Which conferences will Valneva be attending?
Valneva will attend the TD Cowen Annual Health Care Conference and the Van Lanschot Kempen Life Sciences Conference.
What revenue does Valneva forecast for 2025?
Valneva expects to generate between €170-180 million in revenue from its marketed vaccines in 2025.
Who are the key speakers from Valneva at the conferences?
CEO Thomas Lingelbach and CFO Peter Bühler will represent Valneva at the conferences.
How can media and investors contact Valneva?
Media and investors can contact Laetitia Bachelot-Fontaine and Joshua Drumm via their provided email addresses for inquiries.
